Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of autologous BCMA-CART for relapsed/refractory multiple myeloma
ChiCTR2100054874Phase 2Recruiting
- Sponsor
- Beijing Boren Hospital
- Start
- Dec 2021
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BCMA-CART in multiple myeloma (MM), sponsored by Beijing Boren Hospital. Primary endpoints: Safety evaluation index and Efficacy evaluation index. Started Dec 2021; status: recruiting.
02
Drugs
BCMA-CART
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2100054874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054874.